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Summary. Meta-analysis, though increasingly popular 
in clinical medicine, has not found acceptance in 
anatomic pathology. This  paper argues that,  in 
combination with a systematic review of the literature, 
meta-analysis may be usefully applied to pathological 
research and two examples drawn from gynaecological 
pathology (the value of nuclear DNA quantitation in 
predicting progression in low grade cervical intra- 
epithelia1 neoplasia and the difference in prognosis 
between squamous cell carcinoma and adenocarcinoma 
of the cervix) are included to illustrate the methods used 
and to demonstrate some of the difficulties associated 
with these techniques. 
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Introduction 
Overviews of research have long been necessary 
when studies were inconclusive, produced conflicting 
results or when definitive studies were deemed to be 
impossible (Sacks et al. ,  1987). Contemporary 
approaches to providing such overviews include the 
techniques of systematic review and meta-analysis. 
Systematic review permits data from a number of 
different studies to be aggregated allowing the results to 
be interpreted in the context of a given clinical problem. 
Meta-analysis is a quantitative synthesis of data from 
several studies, usually involving the use of statistical 
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methods, which may have been identified on systematic 
review. 
Meta-analysis has not found acceptance in 
pathological research and a medline search combining 
the text words meta-analysis with anatomic pathology, 
surgical pathology and pathology generated no matches. 
This paper argues that the techniques employed in meta- 
analysis can and should be applied to pathological 
research. 
Examples of a systematic review of nuclear DNA 
quantitation in cervical intraepithelial neoplasia (CIN) 
and a meta-analysis of the prognostic implications of 
glandular differentiation in low stage cervical carcinoma 
demonstrate the methods used and illustrate some of the 
problems which may be encountered in performing this 
kind of review. 
Why carry out reviews ? 
Much medical research consists of assessing the 
effect of an intervention either in the healthy individual, 
for example, the epidemiological effect of cigarette 
smoking in healthy adults and the subsequent 
development on carcinoma of the lung and coronary 
heart disease, or in the diseased state. The latter, thera- 
peutic research, most commonly assesses how drugs 
modify the course of disease and uses the randomised 
controled trial as its gold standard for assessing new 
drugs. 
On occasion, existing evidence may be limited to a 
number of studies based on only a few cases. Further 
studies may not be feasible because the disease is rare 
preventing the accumulation of sufficient numbers of 
cases to allow the effect of the intervention and the 
effect of chance to be balanced (Chalmers et al., 1992) 
or because withholding an intervention in a condition 
with a dismal outlook may be considered unethical 
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(Chalmers et al., 1992). To make matters worse a 
number of studies may have produced apparently 
conflicting results. Finally the results obtained in a 
sample of one age range, racial group or in one of the 
sexes may not necessarily be applicable to older or 
younger subjects or to patients of different ethnic origin 
or gender. Since i t  would be difficult to organise a study 
which allowed every possible permutation to  be 
assessed, there has always been a need to synthesise the 
evidence from existing studies allowing a more rational 
approach to patient management. Traditionally this has 
been attempted using the narrative review in which an 
individual attempts to draw meaningful conclusions 
from the, sometimes conflicting results of existing 
studies. Systematic review with or without meta-analysis 
is an alternative to this approach. 
Advantages of systematic review 
A systematic review seeks to impose a structured 
approach to the review of existing data with regard to the 
methods of locating studies,  combining data and 
assessing outcome (Thacker, 1988; Thacker et al., 1996). 
By combining the data from a range of existing studies 
carried out in different localities a systematic review 
resembles a multicentre trial and the review process has 
features in common with primary research (Chalmers et 
al., 1992; Oxman, 1994; Peipert and Bracken, 1997). By 
a simple increase in the size of the sample under study, 
meta-analysis of this data increases the power of the 
statistical analyses (Sacks et al., 1987; Peipert and 
Bracken, 1997) allowing summary descriptive statistics 
to be generated across the range of studies (Thacker, 
1988). It allows a more precise assessment of the impact 
of treatment or risk factors for a disease (Peipert and 
Bracken, 1997) and improves estimates of the magnitude 
of the effect of interventions (Sacks et al., 1987; Thacker 
et al., 1996) such as differences in the drug dosages or 
degree of exposure to an environmental pollutant. The 
relationships between different aetiological features and 
therapeutic modalities may be examined (Thacker et al., 
1996). Since the subgroups contained within an 
individual study may be too small to permit meaningful 
statistical analysis, combining studies may generate 
subgroups which are large enough to permit a statistical 
manipulation (Thacker, 1988). The source studies may 
have originated in a variety of ethnic groups in different 
countries and as a consequence the results are more 
generalisable than those of a single centre or multicentre 
study confined to a single country or continent (Thacker, 
1988; Thacker et al., 1996). Furthermore since a variety 
of investigators are involved in planning and executing 
the studies, investigative bias and subjectivity is 
mitigated (Thacker, 1988). By balancing their outcomes 
with those of larger studies meta-analysis reduces the 
impact of studies consisting of small numbers of patients 
which have "statistically significant" results. As is 
discussed later such studies are more likely to be 
submitted for publication than studies in which the 
results are "not significant" (Koren et a l . ,  1989; 
Easterbrook et al., 1991; Dickersin et al., 1992) and may 
give an exaggerated impression of the effectiveness of a 
therapy but seem likely to continue to be performed 
whilst researchers are judged in terms of their output of 
papers in peer review journals at the expense of their 
contribution to multicentre studies (Newcombe, 1987) 
Ongoing meta-analysis 
By initiating a systematic review soon after the 
introduction of a new intervention accompanied by 
regular updates, with the results of new studies followed 
by the statistical evaluation of a meta-analysis, the value 
of the intervention becomes more rapidly obvious. This 
has obvious advantages in therapeutics where the early 
recommendation of a reliable therapy may be made and 
where a therapy demonstrated to be useless, harmful or 
obsolete can be rapidly identified preventing its further 
use (Chalmers et al., 1992). Thus meta-analyses prevent 
a continued needless use of resources after existing data 
has demonstrated the effectiveness of an intervention 
(Chalmers et al., 1992). Finally the data available at the 
end of a meta-analysis may permit questions which had 
not been posed at the beginning of the individual trials to 
be addressed (Sacks et al., 1987; Peipert and Bracken, 
1997) and the results of the meta-analysis may provide 
indications for future lines of research and help with the 
planning and design of studies (Altman and Elbourne, 
1988; Huque, 1988) 
Limitations of meta-analysis 
Like any review, meta-analyses require suitable 
studies to be available for inclusion (Altman and 
Elbourne, 1988; Thacker et al., 1996). The quality of 
available studies will be variable but (Altman and 
Elbourne, 1988; Thacker et al., 1996) as many studies as 
possible should be identified to maximise the data 
available for review (L'abbe et al., 1987; Oxman 1994). 
It is a lso essential to ensure that the studies are 
"combinable", in terms of ensuring that they employ 
similar methodologies and examine samples drawn from 
similar populations. 
Levels of evidence 
Careful randomization is designed to eliminate bias 
between study groups by ensuring that investigators do 
not determine which patients enter the study or control 
groups thus determining the characteristics of the groups 
and influencing outcomes (Chalmers et al., 1983). As a 
result any difference between the groups is explained by 
chance (Altman, 1991). Variation in the quality of 
randomization has been acknowledged (Schultz et al., 
1994). The random allocation of subjects for study in 
laboratory experiments is achievable (Altman, 1991) 
although much research in anatomical pathology consists 
of non-randomised cohort or case control studies and is 
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Table 1. Types of study design in decreasing order of like hood of bias 
level of evidence of treatment (Chalmers et al. 1987; Altman, 1991; 
Easterbrook et al., 1991 ; Oxman, 1994). 
1. Randomised control trial - lower level of confidence limit exceeds 
signif~cant benefit. 
2. Randomised control trial - lower level of confidence limit does not 
exceed significant benefit. 
3. Non-randomised cohort study. 
4. Non-randornised cohort study - historical study. 
5. Case control study. 
centred on how particular markers differ in benign as 
opposed to malignant disease or in how they assist in 
predicting prognosis and response to therapy. 
Levels of evidence for the effectiveness of study 
design have been proposed (Table 1). According to 
these, observational studies such as case control or 
cohort s tudies  are deemed to be less persuasive 
(Chalmers et al., 1987; Altman, 1991; Oxman, 1994) and 
at a greater risk of bias than randomized studies. I t  is 
argued that they should be analysed separately from 
randomized studies and possibly should never be 
combined at all (Spitzer, 1991; Shapiro, 1994; Feinstein, 
1995; Peipert and Bracken, 1997). It has also been 
suggested that since standard statistical techniques 
assume randomisation of the study sample, studies 
should be randomly selected for inclusion i n  a meta- 
analysis (Thacker, 1988). 
Narrative review versus systematic review and rneta- 
analysis 
Conventional narrative reviews are usually 
constructed by experts with a wide knowledge of the 
field of interest who select the most appropriate, but by 
no means all, of the published data, for inclusion. The 
basis of this selection is not only on the standing of the 
journal in which the article has been published but is 
based on the expert's knowledge of the trustworthiness 
of the researchers and the reputation of their labora- 
tories. Furthermore since they are familiar with research 
in the field, they are also aware of pitfalls in interpreting 
the data such as those which result from variation in 
experimental techniques or design (Eysenck, 1994). The 
most obvious danger in employing reviewers who are 
active in a particular field of research is that they will 
select papers which provide evidence to support a 
hypothesis which they favour. In addition it has been 
suggested that experts when asked to write a review 
spend less time preparing it than non-experts and write a 
review of inferior quality (Oxman and Guyatt, 1993). 
Whilst the final conclusion may not differ from those of 
a narrative review in which no further statistical tests 
have been applied, (Thacker, 1988) it has been suggested 
that unwarranted validity may be applied to the results of 
a meta-analysis because it appears to be a more objective 
and "scientific" pursuit (Thacker, 1988). Methods of 
defining the quality of meta-analysis (Thacker, 1988) 
and standardised reporting of these studies have been 
proposed (Sacks et al., 1987) and are outlined below. 
Location and presentation of data 
I n  common with any research paper the source of 
data, methods of identifying it, the data itself and 
methods of statistical analysis etc should be presented in 
the final written report in sufficient detail to permit the 
reader to repeat the study (Altman and Elbourne, 1988; 
Chalmers et al., 1992; Peipert and Bracken, 1997). 
Organisation of systematic review and meta-analysis 
Hypothesis 
Meta-analyses are performed to test hypotheses 
(Thacker et al., 1996). In this report we will test two 
hypotheses. The first hypothesis is that a polyploid 
nuclear DNA content in cervical intraepithelial neoplasia 
grade I is not associated with progression to higher grade 
CIN or invasive carcinoma. This hypothesis has been 
chosen because it has been previously suggested as a 
suitable pathological topic for systematic review 
(Heatley, 1995,  1998)  and because a small  and 
manageable number of primary studies, which highlight 
some of the difficulties associated with systematic 
review and the process of attempting a meta-analysis, 
are available. Most of the article will deal with the 
methods used in examining this hypothesis. Ultimately 
none of the polypoid cases of CIN progressed. A second 
hypothesis that glandular differentiation in cervical 
carcinoma is associated with a poor prognosis therefore 
complements the first by demonstrating other aspects of 
the techniques of meta-analysis. 
Systematic reviews and meta-analyses confined to 
small numbers of studies and patients are not unusual 
(Schulz et al., 1995). 
Identification of studies 
Meta-analysis requires the combination of existing 
studies. The systematic identification and selection of 
such studies using previously arranged inclusion and 
exclusion criteria is a laborious affair which like any 
primary research requires advance planning (Thacker et 
al., 1996). 
Variations in the results of meta-analysis are often 
dependent on variations in their methodology and in 
particular on which studies the reviewer decides to 
include (Chalmers et al., 1987). The identification of all 
studies or as many as possible is limited if confined to 
standard computer searches such as the National Library 
of Medicine's database "Medline", which it is estimated 
permit the identification of only about 50% of studies, 
even though many more will have been published as 
papers in  peer review journals (Chalmers et al., 1992), 
due to inadequacies in indexing and the failure of 
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Table 2. Criteria for inclusion in systemic review. Table 3. Journals handsearched in performing systemic review. 
Pros~ective studies. Journal of Clinical Patholoav 
Colposcopy and histological confirmation of diagnosis. 
In-situ squamous neoplasia of the cervix. 
v ,  
Journal of Pathology 
Histopathology 
British Journal of Obstetric and Gynaecology 
Follow-up period sufficient to assess potential for regression1 Americal Journal of Obstetrics and ~ ~ n a e c i l o ~ ~  
progression. 
Quantitative analysis of nuclear DNA content. 
Obstetrics and Gvnaecoloav 
authors to describe their own research methods. When 
performing meta-analyses many authors therefore extend 
their searches using a variety of methods such as hand 
searching of journals and following up reference lists in 
known studies. Problems are encountered with both 
methods. Handsearching of journals is time consuming 
and if practicable should be limited to a small number of 
relevant journals. Gotzsche (1987) mentions that in his 
study of double blind trials of two or more non steroidal 
anti-inflammatory drugs used in rheumatoid arthritis he 
found 200 relevant articles which had been published in 
63 different journals! He was thus unable to refine a list 
of journals which should be targeted for further detailed 
hand searching. 
Multiple publication of the same data in a series of 
references (for example, 60 papers and 20 abstracts have 
been traced to a single study (L'abbe et al., 1987)) or 
selection of only a proportion of ava~lable studies and 
failure to mention studies similar to the index paper adds 
to the potential for bias when searching reference lists. 
Identification of studies of nuclear DNA content in 
CIN 
The criteria developed to decide whether a study 
should be included in this review are listed in Table 2. 
Papers were identified using a medline search. In 
addition the index pages of three obstetrics and 
gynaecology and three anatomical pathology journals, 
six in all, published between 1987 and 1996 (Table 3) 
were hand searched for relevant papers. These journals 
were available in this institution and although the 
number of journals and the interval searched was 
restricted, the process took a total of 17 hours. Hand 
searching was facilitated in those journals where a list of 
papers published in each issue of the journal was 
included with the author and subject index at the end of 
each volume and where details of the methodology and 
size of the study was included in the article title. Whilst 
recognising the value of declarative titles (Underwood, 
1997) the alternative of providing a descriptive title 
outlining methods used, the numbers of patients and the 
results saves the analyst much time in obtaining 
unhelpful references. Perhaps the use of an explanatory 
sentence after the title as demonstrated in the Contents 
page of journals such as "Obstetrics and Gynecology" 
and "Gynecological Ontology" represents a suitable 
compromise. In addition the reference lists of known 
papers were scoured. 
Papers likely to be relevant to the review were 
obtained on inter-library loan. 
Studies not published as full papers in peer review 
journals 
A further difficulty in the identification of suitable 
data is that many studies are never published as full 
papers in peer review journals. The data may however be 
available in what is termed the "grey literature" - in short 
reports, abstracts and conference proceedings, technical 
reports, reports submitted by drug companies in pursuit 
of product licences or in government reports and in 
master and doctoral theses and dissertations (Thacker, 
1988; Chalmers et al., 1990, 1992; Easterbrook et al., 
1991; Dickersin et al., 1992). The inclusion of short 
reports and letters, which often do not have summaries 
included on the medline or in published articles is 
important as only 36% of these, proceed to full reports, 
the comparable figure for abstracts is about 50% 
(Goldman and Loscazlo, 1980; Chalmers et al., 1990; 
Scherer et al., 1994). Although some authors confine 
their reviews to published data (Chalmers et al., 1987) it 
is recognised that this under-represents all the data 
available in any field and that failure to include these 
studies from the "grey literature" may lead to radically 
different conclusions. For example, reviews of only 
published papers suggest that multi-drug cytotoxic 
therapy for ovarian carcinoma is of greater efficacy than 
single agent treatment. Inclusion of all available studies 
however shows no significant difference between the 
two methods of treatment (Simes, 1986). Some authors 
argue that data which has not been published in peer 
review journals is unreliable (Sacks et al., 1987). 
A number of investigations have sought to explain 
why certain studies are ultimately published as full 
papers and why some are not. An association between 
the publication of results in peer review journals or 
acceptance for presentations at society meetings on the 
one hand and statistically significant or positive findings 
on the other has been described (Chan et al., 1982; 
Thacker, 1988; Dickersin et al., 1992; Scherer et al., 
1994). Although other authors have failed to find an 
association between statistically significant results and 
publication, significant results were associated with a 
greater chance of multiple publication or publication in 
journals with a higher citation index (Easterbrook et al., 
1991). Other factors which increase the probability of an 
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Table 4. Societies whose Abstract were revlewed in performing the 
systemic review. 
Tha Pathological Society of Great Britain and Ireland. 
The American Gynaecologial and Obstetrical Society. 
The Blair Bell Research Society. 
The British Gynaecological Cancer Society. 
The Central Association of Obstetricians and Gynecologists. 
The Pacific Coast Obstetrical and Gyecological Society. 
The Society of Gynecological Surgeons. 
The South Atlantic Association of Obstetricians and Gynecologists. 
article's publication include having a sample size greater 
than the median (Easterbrook et al., 1991; Scherer et al., 
1994), external funding; especially from government 
agencies such as the United States National Institute of 
Health (Dickersin et al., 1992; Dickersin and Min, 1993) 
and multiple data recruitment sites (Dickersin et al., 
1992; Dickersin and Min, 1993). No association with the 
presence of a comparison group (Dickersin et al., 1992) 
or study type - observational versus clinical trial 
(Dickersin et al., 1992) has been demonstrated. 
Although in one study papers with negative results 
were found to have a greater chance of being rejected 
than those with statistically significant results, despite 
often superior methodologies (Koren et al., 1989), 
follow up by a number of authors indicates that most 
studies which are presented for peer review are 
ultimately published (Easterbrook et al., 1991; Dickersin 
et al., 1992; Scherer et al., 1994) although submission to 
up to six journals may be needed (Scherer et al., 1994). 
In one series only 6 of 124 (4.8%) (Dickersin et al., 
1992) and in another only 9% of repeatedly submitted 
papers were ultimately unsuccessful (Easterbrook et al., 
1991). Thus, under-reporting in the peer review literature 
may be a function of the failure of authors to consider 
their data to be of importance (Easterbrook et al., 1991) 
and to submit it for consideration (Dickersin et al., 1987; 
Chalmers et al., 1992) rather than a reflection of 
publication bias by editors. Reasons cited by authors for 
failure to submit papers include methodological 
problems, failure to analyse the data (Easterbrook et al., 
1991), the need to perform further statistical analyses 
(Dickersin and Min, 1993), negative results following 
statistical analysis (Easterbrook et al.: 1991), results 
which the authors perceive as uninteresting and unlikely 
to be accepted for publication (Koren et al., 1989; 
Dickersin and Min, 1993) - a high importance rating by 
the investigator is an independent statistically significant 
variable on multivariate analysis in determining if the 
paper is published (Easterbrook et al., 1991), - problems 
with CO-investigators (Dickersin and Min, 1993) and 
lack of time to prepare the report (Dickersin and Min, 
1993). In some cases the study may have been 
performed only to enable the pharmaceutical company to 
gain a product licence (Easterbrook et al., 1991). Studies 
which had formed part of a doctoral or masters thesis 
were no more likely to be published as peer review 
papers (Dickersin et al., 1992). 
Aside from suggesting that there is an ethical 
obligation to publish data (Chalmers, 1990; Dickersin et 
al., 1992) steps which will facilitate the identification of 
studies which have not been published include the 
establishment of the Cochrane Centre, and the Online 
Journal of Current Clinical Trials (Dickersin and 
Min, 1993; Scherer et al., 1994). Potential future 
developments include a suggestion that protocols for all 
drug trials should be published in peer review journals 
before commencement of the study (Piantadosi and 
Byar, 1988) and that all trials should be centrally 
registered (Chalmers et al., 1988; Meinert, 1988). 
National research registers, in some instances based on 
the ethical committees which exist in most countries and 
institutions have been established or proposed 
(Easterbrook, 1987; Dickersin et al., 1992; Dickersin and 
Min, 1993; Scherer et al., 1994). These initiatives could 
easily be extended to pathological research. 
Identification of studies not published as full papers to 
peer review journals 
In an attempt to identify additional sources of 
material the proceedings of a number of learned societies 
were screened (Table 4). No additional studies were 
identified. 
Some authorities suggest that locating additional 
material may be facilitated by approaching individuals 
with an acknowledged interest in the field at scientific 
meetings or that investigators who have published 
papers on related subjects should be contacted in an 
effort to identify further unpublished material or to 
clarify details of published studies (Oxman, 1994). In 
my experience neither is a fruitful source of enquiry, in 
particular a total of 20 letters sent to the authors of 
publications, reporting nuclear DNA ploidy analysis in 
CIN lesions, requesting follow up information, yielded 
only four replies! 
Selection criteria for inclusion of studies 
Quality issues are not confined to data in the grey 
literature. Concerns regarding data from papers 
published in peer review journals include study size and 
the quality of study design especially in older studies 
(Gillman and Runyan, 1984). It has been shown that the 
chances of poorly planned and executed trials being 
published as full papers are increased if they show 
extreme results.  As a result a large number of 
statistically significant studies each composed of a small 
number of patients may be published and may give a 
distorted impression of the effect of an intervention 
(Newcombe, 1987). Confining meta-analyses to studies 
which have been published in peer review journals will 
not remove the problems associated with including poor 
quality data. There is therefore a case for being selective 
in deciding which papers to include in the meta-analysis 
and excluding less rigorously executed studies, the 
results of which may be less generalizable (Thacker, 
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1988). 
In many instances it is not possible for a single 
investigator or group to obtain a sizeable sample for 
study. Failure to perform and publish such studies would 
however deprive the literature of the data which they 
provide. An alternative to refusing to publish these 
papers with statistically significant results based on 
small number of patients is to ensure that studies with 
small samples which have yielded negative findings are 
also published (Dickersin et al., 1987). 
Since it has been suggested that most systematic 
reviews or meta-analyses consist of data originating 
from a small number of large studies, the inclusion or 
exclusion of studies comprising small numbers of 
patients has little effect on the ultimate conclusion of the 
review (Chalmers et al., 1987). Indeed some authorities 
recommend that the number of unpublished studies or 
cases which would be necessary to convert statistically 
significant data to statistical insignificance should be 
established. If the number is small then there would be 
cause for concern (L'abbe et al., 1987). 
Determining quality assessment criteria 
To overcome all of these problems it is recom- 
mended that a quality assessment protocol should be 
generated (Peipert and Bracken, 1997) which consists of 
the minimum criteria necessary for a study to be 
included in the systematic review 01. meta-analysis 
(Newcombe, 1987). To some extent this reflects the 
situation with primary research where data may be 
excluded because it is incomplete or because subjects are 
unsuitable - they may be too old, too young or of the 
wrong sex for inclusion in the study. Quality criteria for 
the inclusion/exclusion of such studies have been 
proposed (Peipert and Bracken, 1997).  To avoid 
confirmatory bias, that is the tendency to only select 
those papers which confirm one's own views (Thacker, 
1988; Koren et al., 1989), it is usually recommended that 
the selection of papers be based on scrutiny of the 
Materials and methods sections. The  criteria for 
inclusion in the study are determined (Altman and 
Elbourne, 1988; Thacker, 1988; Oxman, 1994; Thacker 
et al., 1996; Peipert and Bracken, 1997) and the protocol 
prepared (Sacks et al., 1987; Peipert and Bracken, 1997) 
before the papers are read. Some investigators go so far 
as to anonymise photocopies of the Materials and 
methods sections of the papers under consideration 
(L'abbe et al., 1987; Altman and Elbourne, 1988; 
Thacker, 1988; Oxman, 1994; Peipert and Bracken, 
1997) by removing any means of identification except 
for a code number and having a single reviewer (Schultz 
et al., 1995) or two independent reviewers assess the 
paper's suitability for inclusion (Chalmers, 1987; 
Altman and Elbourne , 1988; Thacker, 1988; Thacker et 
al., 1996; Peipert and Bracken, 1997). Discrepancies or 
differences are resolved in conference. 
By avoiding any opportunity to view the results the 
reviewer is not unduly influenced by apparently 
promising results and only methodologically sound 
papers are included (Altman and Elbourne, 1988). 
Whilst this council of perfection is to be applauded it is 
dependent upon the discipline of authors and editors in 
ensuring that the Materials and methods section of every 
paper is a complete account of how the study was 
performed and an accurate predictor of what results can 
be expected. In reviewing the papers for this study I 
found that this was not the case and that i t  was often 
necessary to turn to the summaries and Results sections 
to glean further information thus avoiding the loss of 
useful data gathered in a methodologically sound study. 
Details of the criteria for inclusion/exclusion of 
studies should be included in the final report along with 
a list of all the papers screened. The reasons for the 
inclusion or exclusion of each individual paper should be 
stated (Peipert and Bracken, 1997). 
Inclusion criteria for this study 
The criteria for inclusion of studies in this review are 
listed (Table 2). Following a computerised literature 
search using the Medline database handsearching six 
journals (Table 3) published between 1987 and 1996, 
and searches of the reference lists of the papers thus 
identified, 45 studies of potential interest were located 
(Table 5). 
Outcomes 
As recommended all the papers reviewed and the 
reasons for rejecting any are given in Table 5 (Sacks et 
al., 1987; Peipert and Bracken, 1997). Careful screening 
of the 45 papers enabled the exclusion of the great 
majority. In most instances the papers dealt exclusively 
with invasive carcinomas and were outside the scope of 
the study. In papers dealing with CIN lesions many did 
not include a sufficiently long period of follow-up 
between diagnosis of the patient's CIN lesion and 
treatment to enable an assessment as to whether the 
disease was likely to resolve or not. In some instances 
the studies had been carried out on definitive therapeutic 
specimens. It should be borne in mind however that 
many of the papers assessed in this review described 
comparisons between different groups and were not 
primarily designed to provide follow-up data (Oxman, 
1994). 
At the end of this preliminary selection exercise four 
studies had met the basic criteria for inclusion. Further 
assessment was carried out to ensure that the studies 
were similar enough to be combined (Peipert and 
Bracken, 1997). Since different studies may use a variety 
of methodologies (Peipert and Bracken, 1997) i t  was 
necessary to ensure that it was possible or appropriate to 
pool the studies for statistical analysis (Thacker et al., 
1996). Of the four candidate studies which met the initial 
criteria, two were large studies one of 100 patients and 
the other of over 300 patients. The third was a study of 
32 patients and the fourth a study of 59 patients in which 
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Table 5. Studies considered for inclusion in systemic review. 
AUTHOR SELECTEDIEXCLUDED 
l .  Barry Walsh et al., 1993 
2. Bibbo et al., 1989 
3. Bocking et al., 1986 
4. Chacho et al., 1990 
5. Clavel et al., 1992 
6.Connor et al., 1993 
7. De Vita et al., 1990 
8. Dudzinsky et al., 1987 
9. Elias Jones et al.. 1986 
10. Evans and Monaghan 1983 
l 1. Fletcher et al.. 1991 
12. Freni, 1975 
13. Fuetal., 1978 
14. Fu et al., 1981 
15. Fu et al., 1982a,b 
16. Fu et al., 1983 
17. Fujii et al., 1984 
18. Hanselaar et al., 1988 
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Exclude 
Select 
Exclude 
Exclude 
Exclude 
Exclude 
Select 
Exclude 
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Exclude 
Exclude 
Exclude 
Select 
Select 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Select 
Unsuitable 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
1989 Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
Exclude 
REASON FOR INCLUSION(C0MMENTS 
lnvasive carcinoma - case report 
Follow up of 302 in-situ cases 
Reviews established invasive cases. Follow up less than 3 months 
No follow up available 
No follow up available 
Invasive carcinoma - series 
Follow up in 4 of 59 cases 
No follow up available for CIN patients. 
No follow uprrechnical paper 
No follow up 
Based on study of cell lines. No follow up 
No follow up 
lnvasive adenocarcinoma series 
No follow up available 
No follow up available 
Review of established invasive cases 
Compares CIN 3 with and without invasion. Not a follow up study 
No follow up 
Study based on cytological findings - no colposcopic/histologic verification 
No follow up 
No follow up 
No follow up data 
Invasive carcinoma 
No follow up 
Study includes invasive carcinomas from sites not confined to the uterine cervix 
Study based on chromosomal counts, not DNA quantitation 
Invasive carcinoma 
Invasive carcinoma 
Animal study 
Invasive carcinoma 
No follow up 
No follow up 
Invasive carcinoma 
No follow up 
No follow up 
No follow up 
No follow up 
No follow up 
No follow up 
No follow up 
No follow up 
Invasive carcinoma 
follow-up is available for only 4. 
Whilst there is no reason for excluding the study 
with follow up in 4 patients on the basis of a small 
sample size alone, other variables such as the fact that 
follow-up was available in a minority of patients all of 
whom had high grade CIN lesions placed it outside the 
scope of the hypothesis. The importance of ensuring that 
patients with diseases which have different causal factors 
are not compared is also important (Eysenck, 1994). The 
study of 32 patients by Fu et al. (1978) was based on 
patients who were exposed to diethylstilbestrol (DES) in 
utero. Since DES is known to predispose to malignancy, 
especially adenocarcinomas, of the female genital tract 
there would appear to be a prima facie objection to 
including these data. Although inclusion of this study 
would increase the number of women with polyploid 
CIN 1 to 60, an approximately twofold increase in 
incidence of squamous CIN has been described in DES 
exposed women (Robboy et al., 1984). For these 
biological rather than statistical reasons this study was 
also excluded. A further potential objection is that since 
this study shares some of the authors of another study 
(Fu et al., 1981), it is possible that the same patients had 
been included in both study groups. As a result their 
effects or findings could be duplicated exaggerating bias. 
On examination of the latter study the authors indicate 
that it consisted of a distinct sample of patients. The 
common authorship was not therefore a reason to 
exclude one or other study. 
Although there was some variation in terminology 
Meta-analysis in anatomic pathology 
Table 6. Numbers of cases of polyploid and aneuploid cases of low and high grade CIN which persistedlregressed of progressed to higher grade 
disease In three studies. 
POLYPLOID ANEUPLOID 
Persistedlregressed Advanced Persistedlregressed Advanced 
Fu et al.. 1978 CIN 1 
CIN 213 
Fu et al.. 1981 CIN 1 
CIN 213 
Bibbo et al., 1989 CIN l 12 0 17 0 
CIN 213 41 18 85 24 
used to describe the grades of intraepithelial neoplasia, 
consistency of grouping (Sacks et al., 1987; Eysenck, 
1994) was possible in each paper by classifying the 
patients studied into high grade (moderate or severe 
dysplasia, CIN 2 or 3) and low grade (mild dysplasia, 
CIN 1). Review indicated that similar methods of DNA 
quantitation were used in both papers. Although it is 
recognised that studies using different techniques may 
need to be included in meta-analyses to increase their 
statistical power and provide additional opportunities to 
study the effects of interventions, Hanselaar et al., 
(1991) found that data may not be interchangeable 
between techniques of DNA quantitation. Peipert and 
Bracken (1997) have highlighted the problems which 
may be caused if studies follow different methodologies 
and emphasises  the importance of ensuring that 
protocols are combinable (Sacks et al., 1987; Peipert and 
Bracken, 1997) with object ive measurements  of 
heterogeneity being advised (Sacks et al., 1987; Thacker 
et al., 1996). 
None of the 42 (0%) cases of CIN 1 which was 
polyploid in the two remaining studies progressed to a 
higher grade lesion although 14 of 37 (38%) aneuploid 
cases did (Table 6). Confidence intervals of 0-7.1% for 
the percentage of polyploid CIN 1 lesions which may be 
expected to advance can be calculated using this data. 
(Had the DES exposed patients been included the 
confidence interval would be 0-5%). It is possible also to 
calculate that it would be necessary to find no evidence 
of progression in a sample size in excess of about 300 
cases of polyploid CIN 1 to predict that the risk of 
progression in the general population was under 1% (ie 
confidence interval 0-1%) (Table 6). 
Other methods for presenting results 
The pooling of data from the studies in a meta- 
analysis does not necessarily involve the combination of 
the actual data but is accomplished by calculating 
differences of effect for each study in the form of an 
odds ratio with confidence intervals followed by the 
construction of a weighted estimate of the effects of the 
intervention (Altman and Elbourne, 1988). As a result 
data is presented study by study rather than as for a 
combined sample. This may be presented graphically 
either in the form a linear plot graph or more usually in 
the form of a bar chart (often termed a "blobograrn") 
with evidence of a positive correlation on one side and 
evidence of a negative correlation on the other side of a 
midline indicator of no effect (L'abbe et al., 1987; 
Altman and Elbourne, 1988; Thacker et al., 1996; 
Peipert and Bracken, 1997). Reflecting a process often 
adopted in narrative review, simple vote counting, that is 
the description of the number of studies with evidence of 
a positive correlation as opposed to the number with a 
negative correlation, may be utilized. Most meta- 
analyses however include a statistical analysis, the most 
usual test performed being the Mantel Haenszel test 
(L'abbe et al., 1987; Altman and Elbourne, 1988; Peipert 
and Bracken, 1997) but with Chi-squared, regression 
analysis and others being performed on occasion (L'abbe 
et al., 1987). 
Several factors may have an effect on outcomes, and 
in this situation, multivariate analysis may be more 
appropriate than univariate analysis (Eysenck, 1984, 
1994; L'abbe et al., 1987). The appropriateness of the 
statistical tests used has been questioned since these tests 
are designed for analysis of primary data (L'abbe et al., 
1987; Thacker, 1988; Eysenck, 1994; Peipert and 
Bracken, 1997) and the development of statistical 
methods specifically for meta-analyses (in particular 
tests which allow combination of studies other than 
randomized control trials) has been proposed (Thacker, 
1988). 
The description of confidence intervals or standard 
deviations, as in the above example, is also encouraged 
(L'abbe et al., 1987; Newcombe, 1987; Sacks et al., 
1987; Altman and Elbourne, 1988; Thacker, 1988, 1996; 
Oxman, 1994) although those in which the confidence 
interval for the size of the effect excludes zero are likely 
to be preferred (Newcombe, 1987). 
Confounding factors in meta-analysis 
Tests of heterogeneity between studies are advisable 
to ensure one is not combining fundamentally different 
studies, a process which has been likened to adding 
apples and oranges (Eysenck, 1984, 1994; Thacker, 
1988; Peipert and Bracken, 1997). Statistical analyses 
should also address the extent to which the study results 
depend upon variations in characteristics (L'abbe et al., 
1987). Interventions are likely to vary from study to 
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Table 7. Sensitivity analysis examines the effect of: 
- Changing inclusion criteria 
- Effects of includinglexcluding trials which do not satisfy selection 
criteria 
- Effects includinglexcluding unpublished studies 
- Reanalysing data using a reasonable range of results where the data 
are not available 
- Reanalysis using alternative statistical methods 
Table 8. Criteria for inclusion of series in a meta-analysis of survival in 
squamous cell versus adenocarcinoma and adenosquamous carcinoma 
of the cervix. 
Data availabe for squamous cell and adenoiadenosquamous 
carcinoma. 
Mucin stains performed in cases which morphologically appear to be 
squamous cell carcinomas to identify squamous carcinomas with 
mucin secretion (adenosquamous carcinomas). 
Survival/mortality data available for five or more years after diagnosis. 
Data presented in numerical form in text or table. 
Details of tumour stage included. 
study, for example in a pathological study involving 
immunohistochemistry, the concentration of primary 
antibody or the incubation conditions may vary. 
Attempts to correlate results with variations in such 
study characteristics and to determine how sensitive the 
results are to the way in which the study is carried out 
are advised (Oxman, 1994; Peipert and Bracken, 1997). 
This is termed sensitivity analysis and the points which 
should be included in such an analysis are listed in Table 
7 (Chalmers et al., 1987; Sacks et al., 1987; Oxman, 
1994; Thacker et al., 1996; Peipert and Bracken, 1997). 
Practical demonstration of tests of heterogeneity, 
graphical representation of results and the Mantel- 
Haenszel test 
Squamous cell and adenocarcinoma of cervix 
To demonstrate a situation in which there was no 
evidence of heterogeneity, a review of published series 
of cervical carcinoma was carried out to examine the 
hypothesis that the prognosis in squamous cell  
carcinoma in which there is no evidence of glandular 
differentiation is better than in adenocarcinomas and in 
squamous cell carcinomas in which there is evidence of 
glandular differentiation as demonstrated morpho- 
logically or with mucin stains (squamous carcinoma 
with mucin secretion/adenosquamous carcinomas). The 
criteria for inclusion are presented in Table 8 the studies 
identified are detailed in Table 9 with the reasons for 
exclusion if appropriate. The results of the three series 
studied are given in Table 10. Although one of these has 
a relatively high survival rate the standard test for 
heterogeneity is nonsignificant indicating that it is not 
unreasonable to conduct a meta-analysis. The relative 
risks for mortality are illustrated in the Figure 1. The 
Table 9. Reasons for excluding studies of prognostic features in 
adenocarcinoma of the cervix. 
Kilgore et al., 1988 
Langlois et al.. 1996 
Hale et al., 1991 
Harrison et al., 1993 
Terada et al., 1988 
Colgan et al., 1993 
Fu et al., 1982 
Schorrock et al., 1990 
Gallup et al., 1985 
Greer et al., 1989 
Hopkins et al., 1988 
Ireland et al., 1987 
Randal et al., 1988 
Saigo et al., 1986 
Yazigi et al.. 1990 
Buckley et al., 1988 
Mucin stains not used, data not presented in 
numericalltabular form 
Data not given in numerical/tabular form 
Results not presented as table, stages 1 b/2a 
combined. 
Only 67% of patients had 5 year survival 
Mucin stains not used 
No follow up data 
Data for squamous cell carcinoma not included 
No follow up or staging data 
Follow up available for only 2 years in some 
cases 
Follow up less than 5 years in some cases 
Mucin stains not done 
Follow up for 3 years only 
Mucin stain not performed 
Data for squamous carcinoma not included 
Deals with disease free not absolute survival 
rate 
Deals with regional nodal and distant 
recurrence not surevival rate 
Table 10. Five year survival rate in patients with squamous cell 
carcinoma compared to patients with glandular differentiation in their 
carcinoma. 
SQUAMOUS CELL GLANDULAR 
CARCINOMA DIFFERENTIATION 
Survived Died Total Survived Died Total 
Bethwaite et al., 1992 77 26 103 20 19 39 
Benda et al., 1985 32 3 35 16 1 17 
Wheeless et al.. 1970 242 191 433 24 34 58 
Mantel-Haenszel weighted relative risk of mortality 
(squamous relative to adeno) for the three studies 
combined is 0.69 (95% confidence intervals 0.56 - 0.86). 
Thus the risk of mortality for patients with squamous 
carcinoma in 69% of that of patients with adeno- 
squamous carcinoma. 
Discussion 
The discussion of any meta-analysis should 
complete the analysis begun with the presentation of 
data and their statistical analysis, in the same manner as 
the discussion of any research paper. A s  with a 
conventional paper, these should be discussed in the 
context of the existing literature on the subject (Thacker, 
1988; Oxman, 1994; Thacker et al., 1996). Reflecting 
the hybrid nature of these papers, there are advantages in 
having an individual with recognized expertise in the 
field participate in the construction of the discussion as 
he can evaluate methodological weaknesses and assess 
the validity of the data in the context of the existing 
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literature (Eyseenck, 1994). His expertise will eg 
provide a knowledge of relevant basic science research 
and may provide an explanation for the findings 
(Oxman, 1994) or indicate alternative explanations for 
them (Thacker, 1988). 
Many of the factors which are usually included in a 
discussion section have already been dealt with in the 
methods and results sections of this paper. In this study a 
strict adherence to preselected criteria reduced the 
number of studies available for inclusion to two in the 
first review and three in the second. Whilst less rigid 
criteria or a less strict adherence to the criteria may have 
increased the number of studies available for inclusion 
they would also have increased the potential for bias. 
One of the papers recovered (Hanselaar et al., 1992) 
consisted of retrospective reviews of cytology in patients 
who had had established invasive carcinomas of the 
cervix diagnosed some years later. Although these data 
might have been included in a narrative review they 
were excluded from this study because they did not meet 
the criteria outlined in Table 2, in particular the 
prospective nature of the surveys, for inclusion. Further- 
more the study was based on cytological specimens 
originally diagnosed as negative or showing low grade 
abnormalities in patients found later to have micro- 
invasive stage 1A or stage 1B squamous cell carcinoma, 
an average of 30 to 33 months later. Colposcopy had not 
been carried out at the time of initial presentation for 
screening and the full range of abnormalities on the 
cervix may not have been visualized. Thus it is possible 
that the original smear may not have sampled an existing 
high grade or even invasive lesion. 
Although subgroup analysis may be of value, 
interpretation of these results requires particular care 
since it may result in some patients being denied an 
intervention or because it may misdirect research 
resulting in the waste of resources (Oxman and Guyatt, 
1992). Some authors advocate reliance on the overall 
results to indicate the likely effect on a particular 
subgroup. Criteria for subgroup analyses have been 
proposed (Yusuf et al., 1991). Any conclusions and 
recommendations for future changes in practice should 
be in proportion to the strength of the evidence provided 
(Oxman, 1994) and should include an assessment of all 
Pooled Relative Risk 
Fig. 1. This "blobogram" demonstrates the relative risk of death for patients described in three studies (Wheless et al., 1970; Benda et al., 1985; 
Bethwaite et al., 1992). The index line at the centre of the diagram identifies an equal risk, the point at which series in which the risk of death for 
patients with squamous cell carcinoma was the same as that for adenocarcinoma would lie. In two studies the risk of death in patient with squamous 
cell carcinoma was less than that for patients with adenocarcinoma as demonstrated by the heavy line being drawn to the left of the index line. In the 
remaining study in which the risk of death was greater for patients with squamous cell carcinoma is denoted by a heavy line to the right of the index 
line. Confidence intervals are given for each study. The overall risk when the studies have been combined is denoted as the pooled relative risk. 
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likely side effects of the intervention (Oxman, 1994) eg 
in this instance a prospective study of at least 300 
patients with polyploid CIN 1 should be followed to 
ensure that there is no evidence of disease progression. 
Finally whilst meta-analyses may include the 
synthesis of the best available data, it must be 
remembered that this may not be universally applicable 
outside a study setting especially in community practice 
(Thacker, 1988). 
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